Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Everolimus Versus MMF in Lung Transplant Recipients

Next Previous
Trial Profile

Everolimus Versus MMF in Lung Transplant Recipients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 May 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate mofetil (Primary) ; Ciclosporin; Prednisolone
  • Indications Bronchiolitis obliterans; Lung transplant rejection
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 21 Apr 2012 Primary endpoint results presented at the 32nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
  • 21 Apr 2012 Additional descriptors, treatment table details, study initiation and completion dates, patient numbers (updated from 100 to 190) and primary study endpoint added
  • 21 Apr 2012 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top